Skip to main content

Table 2 Select immunotherapy agents and ongoing immunotherapy clinical trials in RCC

From: Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma

Ongoing clinical trials for check point inhibitors
 Trial National clinical trial identifier Status Disease setting
 Neoadjuvant durvalumab +/− tremelimumab NCT02762006 Recruiting Neoadjuvant
 Neoadjuvant pembro NCT02212730 Recruiting Neoadjuvant
 Neoadjuvant nivolumab NCT02595918 Recruiting Neoadjuvant
 Neoadjuvant nivolumab NCT02575222 Recruiting Neoadjuvant
 Nivo vs. nivo + bev vs. nivo + ipi NCT02210117 Recruiting Neoadjuvant
 Nivo pre and post-surgery NCT02446860 Recruiting Neoadjuvant/adjuvant
 Phase I pembro + pazopanib NCT02014636 Recruiting Refractory
 Phase III nivo vs. everolimus NCT01668784 Stopped early and reported in 2015 Refractory
 Nivo + sunitinib or pazopanib or ipi NCT01472081 Active, not recruiting Refractory
 Pembro + RT NCT02318771 Recruiting Refractory
 Phase Ib/II pembro + len in solid tumors NCT02501096 Recruiting solid tumors including RCC Refractory
Ongoing IL-2 based clinical trials
 Trial National clinical trial identifier Status
 HD IL-2 + HQ NCT01550367 Recruiting
 IL-2 +/− SBRT NCT02306954 Recruiting
 IL-2 +/− RT NCT01896271 Recruiting
 PROCLAIM NCT01415167 Registry of HD IL-2 patients
 IL2 + entinostat NCT01038778 Ongoing, presented 2016
  1. Abbreviations: Ipi ipilimumab, nivo nivolumab, atezo atezolimumab, bev bevacizumab, pembro pembrolizumab, len lenvatinib, HQ hydroxychloroquine, SBRT stereotactic body radiation therapy, RT radiation therapy